More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$111628661
EPS
-0.19
P/E ratio
--
Price to sales
1.87
Dividend yield
--
Beta
1.467409
Previous close
$2.81
Today's open
$2.89
Day's range
$2.52 - $2.91
52 week range
$2.25 - $5.08
show more
CEO
Charles D. Goodwin
Employees
205
Headquarters
Clearwater, FL
Exchange
Nasdaq Global Select
Shares outstanding
42124023
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Apyx Medical Corporation (APYX) Presents at 2026 UBS Global Healthcare Conference Transcript
Apyx Medical Corporation ( APYX ) 2026 UBS Global Healthcare Conference November 9, 2026 10:15 AM EST Company Participants Charles Goodwin - President, CEO & Director Conference Call Participants Patrick Andrew Wood - UBS Investment Bank, Research Division Presentation Patrick Andrew Wood UBS Investment Bank, Research Division Thanks for joining. And massive thank you to Charlie Goodwin for agreeing to do this from Apyx Medical's, CEO.
Seeking Alpha • Nov 9, 2026

Apyx Medical Q3 Earnings Call Highlights
Apyx Medical NASDAQ: APYX reported a 9% increase in third-quarter 2026 revenue, driven by sales of its AYON body contouring system in the United States and international demand for Renuvion. The company also narrowed its full-year operating expense target while reaffirming its revenue outlook.
MarketBeat • Nov 5, 2026

Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript
Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction handpiece for the AYON system in the third quarter Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla.
GlobeNewsWire • Nov 5, 2026

Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates
Apyx Medical (APYX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.05 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the third quarter of fiscal year 2026 will be released before markets open on Thursday, November 5th.
GlobeNewsWire • Oct 22, 2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) on behalf of the company's shareholders. The investigation seeks to determine whether Apyx Medical Corporation's directors breached their fiduciary duties in connection with recent corporate actions.
PRNewsWire • Oct 22, 2026

Apyx Medical Corporation to Participate in Upcoming Investor Conferences
CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will present at the following investor conferences: UBS Global Healthcare Conference – November 9-11, 2026 (Miami, FL) Management will participate in a fireside chat at 10:15am ET and will host one-on-one meetings with investors on Monday, November 9.
GlobeNewsWire • Oct 21, 2026

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality
CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality.
GlobeNewsWire • Sep 29, 2026

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.
MarketBeat • Aug 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Apyx Medical Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.